CorticorpNews
Back to Finance
Expand

Updated

Novo said its Wegovy injection lowered body mass index and obesity rates in children in a trial, CNBC Top News reported on November 16, 2026. Wegovy is already approved to treat obesity in children ages 12 and older. There are currently no approved medications for children under 12.

1 outlet · 1 article · first seen Nov 16, 10:10 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • XLV closed at 187.88, down 0.51%, on 2026-11-16. Listed for: Health Care sector ETF.
  • XLV fell 0.51% to 187.88 on 2026-11-16, inside half of its own 60 session daily standard deviation. Same session, a stored story tagged Health Care: Novo reports Wegovy trial lowers BMI and obesity rates in children Stored for the 2026-11-16 session.

Every source article